TGFB1 and cholangiocarcinoma: Additionally, TGF-β/SMAD signaling interacts with the Wnt pathway by inhibiting β-catenin phosphorylation and nuclear translocation, thereby reducing CCA proliferation and migration and enhancing the efficacy of Pemigatinib [26].